Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer …

Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer …

MINDACT is a phase III, randomized, prospective study comparing the use of MammaPrint 70-gene assay with clinical-pathological criteria (current standard of care) for selecting early breast cancer patients who should be treated with adjuvant chemotherapy.

(Visited 1 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.